Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;16(3):272-9.
doi: 10.1038/tpj.2015.54. Epub 2015 Aug 11.

AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin

J B Kjersem  1 , M Thomsen  2 , T Guren  2 , J Hamfjord  1 , G Carlsson  3 , B Gustavsson  3 , T Ikdahl  4 , G Indrebø  5 , P Pfeiffer  6 , O Lingjærde  7   8 , K M Tveit  2 , Y Wettergren  3 , E H Kure  1
Affiliations

AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin

J B Kjersem et al. Pharmacogenomics J. 2016 Jun.

Abstract

The objective of the study was to investigate whether specific single nucleotide polymorphisms (SNPs) with influence on drug transport, biotransformation and repair mechanisms are associated with treatment outcome and toxicity in metastatic colorectal cancer (mCRC). We genotyped blood samples from 519 mCRC patients treated with first-line 5-fluorouracil and oxaliplatin +/- cetuximab for 17 SNPs in 10 genes involved in membrane transport (ABCC1 and ABCC2), drug biotransformation (GSTP1 and AGXT) and DNA repair (ERCC1, ERCC2, XRCC1, XRCC3, XPG and MSH6). The AGXT-rs34116584 and the ERCC2-rs238406 polymorphisms were significantly associated with progression-free survival (P=0.002 and P=0.001, respectively). Associations between 18 toxicity variables and SNPs were identified, although none were significant after Bonferroni correction for multiple comparisons. The study identified SNPs of potential use as markers of clinical outcome in oxaliplatin-treated mCRC patients. If validated in other studies, they could improve the selection of therapy in mCRC.

Trial registration: ClinicalTrials.gov NCT00145314.

PubMed Disclaimer

References

    1. Lancet. 2010 Mar 20;375(9719):1030-47 - PubMed
    1. Bioinformatics. 2008 Dec 15;24(24):2938-9 - PubMed
    1. J Clin Oncol. 2001 Dec 1;19(23):4298-304 - PubMed
    1. J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 - PubMed
    1. Cancer Lett. 2005 Jun 8;223(2):219-26 - PubMed

Publication types

MeSH terms

Associated data